Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

How does the newly EMA approved shorter treatment regiment [sic!] impact ENTA royalties?

The effect on ENTA royalties is negligible. Cirrhotic (Child-Pugh A), non-GT3 patients are a small (single-digit) proportion of Mavyret patients, and the newly approved 8-week regimen in the EU affects only 1/3 of the royalties from this patient pool (by shortening the approved regimen from 12w to 8w).

Moreover, the patient pool in question is now be more likely to use Mavyret in the first place, offsetting some (or all) of the royalty effect from a shorter duration.